In this video, Scarlett Gomez, MD, PhD, discusses the significance of the private public collaboration between the National Cancer Institute’s Surveillance Epidemiology, and End Results program and the Oncotype DX Genomic Prostate Score assay in investing patterns in prostate genomic testing.Gomez is a professor in the department of epidemiology and biostatistics at the University of California, San Francisco.
Rapid genetic testing model found feasible for patients with prostate cancer
March 31st 2023"In our sample, nearly 10% of patients [with prostate cancer] had a gene variant that made them eligible for effective new therapies, with faster results than traditional referral for genetic testing and counseling,” said Maria I. Carlo, MD.
Destigmatizing Urology: Dr. Pruthi discusses mental health
May 23rd 2022“I think we often encourage our patients to share concerns about depression, anxiety, and other mental health conditions, yet are less likely ourselves to seek help due to this issue of stigma,” says Raj S. Pruthi, MD, MHA, FACS.
Study evaluates polygenic risk score for prostate cancer risk prediction
March 18th 2023“Vanderbilt researchers are participating in numerous projects related to PRS and disease risk; studies such as this highlight the importance of evaluating whether novel clinical tools actually enhance care,” said Kerry Schaffer, MD.
Study results suggest prostate cancer classification of ‘very low risk’ may no longer be necessary
March 13th 2023"We think this is an important call to action for the NCCN to follow in the footsteps of the AUA, who recently removed VLR from its prostate cancer guidelines in its most recent update," says Kevin Shee, MD, PhD.
2 Clarke Drive
Cranbury, NJ 08512